AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8944997 — intervention group
Group type: COMPARATOR
Intervention: No leukocyte filters
Number of subjects: 50
Study 1955654 — intervention group
Group type: EXPERIMENTAL
Intervention: Pefloxacin 400 mg every 12 hours for 3 days (first dose 800 mg)
Number of subjects: 38
Study 6814284 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal immunotherapy with Glu‐Rye (10-week course)
Number of subjects: 16
Study 6814284 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal immunotherapy with Glu‐Rye
Number of subjects: 16
Study 6814284 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 30670004 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower limb lifting exsanguination technique (Group A)
Number of subjects: 236
Study 30670004 — intervention group
Group type: COMPARATOR
Intervention: Squeeze exsanguination method (Group B)
Number of subjects: 236
Study 28431533 — intervention group
Group type: EXPERIMENTAL
Intervention: Bikram yoga intervention (3-5 classes per week for 16 weeks)
Number of subjects: 63
Study 28431533 — intervention group
Group type: COMPARATOR
Intervention: No treatment control group
Number of subjects: 63
Study 25689245 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular insulin
Number of subjects: 42
Study 25689245 — intervention group
Group type: COMPARATOR
Intervention: Glargine insulin
Number of subjects: 42
Study 23597356 — intervention group
Group type: EXPERIMENTAL
Intervention: Legacy for Children intervention (parenting groups for 3 to 5 years)
Number of subjects: 574
Study 21494767 — intervention group
Group type: COMPARATOR
Intervention: Ritodrine
Number of subjects: 20
Study 21494767 — intervention group
Group type: COMPARATOR
Intervention: Atosiban
Number of subjects: 20
Study 21494767 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 19139439 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (15 weeks) followed by surgery (arm A)
Number of subjects: 126
Study 19139439 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (12 weeks) followed by chemoradiotherapy (3 weeks) followed by surgery (arm B)
Number of subjects: 126
Study 19139439 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy (arm B)
Number of subjects: 126
Study 16815649 — intervention group
Group type: COMPARATOR
Intervention: SIPPV
Number of subjects: 0
Study 16815649 — intervention group
Group type: EXPERIMENTAL
Intervention: VG
Number of subjects: 0
Study 15084982 — intervention group
Group type: EXPERIMENTAL
Intervention: PR-350
Number of subjects: 48
Study 15084982 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 48
Study 11439795 — intervention group
Group type: EXPERIMENTAL
Intervention: Blind intubation using the intubating laryngeal mask airway (blind‐ILM)
Number of subjects: 54
Study 11439795 — intervention group
Group type: COMPARATOR
Intervention: Fibreoptic-guided orotracheal intubation using an Ovassapian airway (FOS‐OA)
Number of subjects: 54
Study 9564208 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (N = 8)
Number of subjects: 51
Study 9564208 — intervention group
Group type: COMPARATOR
Intervention: Placebo (N = 9)
Number of subjects: 51
Study 9564208 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine and Placebo (combined sample of 17 cocaine-abusing depressed alcoholics)
Number of subjects: 51
Study 9564208 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine-abusing depressed alcoholics (N = 17)
Number of subjects: 51
Study 9564208 — intervention group
Group type: COMPARATOR
Intervention: Non-cocaine abusing depressed alcoholics (N = 34)
Number of subjects: 51
Study 9301387 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone
Number of subjects: 10
Study 9301387 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 2795873 — intervention group
Group type: EXPERIMENTAL
Intervention: Temperature-based, rate-modulated pacing
Number of subjects: 3
Study 2795873 — intervention group
Group type: COMPARATOR
Intervention: Non-rate modulated pacing
Number of subjects: 3
Study 363434 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow release oxprenolol (SRO) once daily
Number of subjects: 16
Study 363434 — intervention group
Group type: COMPARATOR
Intervention: Conventional oxprenolol (CO) once daily
Number of subjects: 16
Study 363434 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow release oxprenolol (SRO)
Number of subjects: 16
Study 363434 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning dosing of SRO
Number of subjects: 16
Study 363434 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening dosing of SRO
Number of subjects: 16
Study 31169381 — intervention group
Group type: EXPERIMENTAL
Intervention: ROOTS intervention
Number of subjects: 0
Study 31169381 — intervention group
Group type: EXPERIMENTAL
Intervention: Embedded assessments
Number of subjects: 0
Study 31169381 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention intensity
Number of subjects: 0
Study 28809610 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabazitaxel 20 mg/m2 (C20)
Number of subjects: 1200
Study 28809610 — intervention group
Group type: COMPARATOR
Intervention: Cabazitaxel 25 mg/m2 (C25)
Number of subjects: 1200
Study 26299196 — intervention group
Group type: COMPARATOR
Intervention: XP (6 cycles of capecitabine)
Number of subjects: 458
Study 26299196 — intervention group
Group type: EXPERIMENTAL
Intervention: XPRT (2 cycles of XP + RT 45 Gy/25 fraction with capecitabine + 2 cycles of XP)
Number of subjects: 458
Study 26299196 — intervention group
Group type: COMPARATOR
Intervention: XP
Number of subjects: 458
Study 26299196 — intervention group
Group type: EXPERIMENTAL
Intervention: XPRT
Number of subjects: 458
Study 23441835 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence Therapy (AT)
Number of subjects: 10
Study 21221689 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra plus MTX
Number of subjects: 54
Study 21221689 — intervention group
Group type: COMPARATOR
Intervention: MTX alone
Number of subjects: 54
Study 21221689 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra
Number of subjects: 54
Study 19422435 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensory retraining
Number of subjects: 186
Study 19422435 — intervention group
Group type: COMPARATOR
Intervention: Control group (no sensory retraining)
Number of subjects: 186
Study 19422435 — intervention group
Group type: EXPERIMENTAL
Intervention: Age factor
Number of subjects: 186
Study 19422435 — intervention group
Group type: EXPERIMENTAL
Intervention: Type of surgery
Number of subjects: 186
Study 17719468 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan 160 mg once daily for 6 months followed by 6 months of single-blind Val in both groups
Number of subjects: 76
Study 17719468 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 17719468 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 76
Study 15064638 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic culture after acute infectious exacerbations of chronic rhinosinusitis
Number of subjects: 113
Study 15064638 — intervention group
Group type: COMPARATOR
Intervention: Baseline postoperative control cultures of the ethmoid sinus
Number of subjects: 113
Study 15064638 — intervention group
Group type: EXPERIMENTAL
Intervention: Empirical therapy based on baseline culture data
Number of subjects: 113
Study 11478829 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glutamine (0.45 g kg(‐1)day(‐1)) for eight weeks
Number of subjects: 8
Study 11478829 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 9929659 — intervention group
Group type: EXPERIMENTAL
Intervention: Butanol delivery during normal respiration
Number of subjects: 10
Study 9929659 — intervention group
Group type: COMPARATOR
Intervention: Filtered medical air
Number of subjects: 10
Study 7798804 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasminogen activation using streptokinase in blood suspensions of diabetic patients
Number of subjects: 37
Study 7798804 — intervention group
Group type: COMPARATOR
Intervention: Plasminogen activation using streptokinase in blood suspensions of healthy subjects
Number of subjects: 37
Study 3282895 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose
Number of subjects: 20
Study 3282895 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31331583 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg of Panax Ginseng twice daily for four weeks
Number of subjects: 62
Study 31331583 — intervention group
Group type: COMPARATOR
Intervention: Placebo twice daily for four weeks
Number of subjects: 62
Study 28364587 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral group therapy (CBGT) for OCD, involving family members in two sessions, 12 sessions total.
Number of subjects: 35
Study 25609546 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous tibial nerve stimulation (PTNS) using adhesive skin surface electrodes for 4 weeks
Number of subjects: 100
Study 25609546 — intervention group
Group type: COMPARATOR
Intervention: Solifenacin succinate (SS) for 4 weeks
Number of subjects: 100
Study 25609546 — intervention group
Group type: COMPARATOR
Intervention: Comparison between PTNS and SS
Number of subjects: 100
Study 23178737 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 min/week aerobic exercise for four months
Number of subjects: 319
Study 23178737 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 319
Study 21865947 — intervention group
Group type: EXPERIMENTAL
Intervention: Mastery Learning (ML)
Number of subjects: 50
Study 19291551 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency Medical Services research under exception from informed consent
Number of subjects: 844
Study 19291551 — intervention group
Group type: EXPERIMENTAL
Intervention: Reasons for not enrolling patients in the study
Number of subjects: 844
Study 16408442 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment group treated as same as adult patients with diabetes mellitus
Number of subjects: 1173
Study 16408442 — intervention group
Group type: COMPARATOR
Intervention: Ordinary treatment group
Number of subjects: 1173
Study 15329366 — intervention group
Group type: EXPERIMENTAL
Intervention: saquinavir/ritonavir 1000/100 mg twice-daily
Number of subjects: 20
Study 15329366 — intervention group
Group type: EXPERIMENTAL
Intervention: saquinavir/ritonavir 2000/100 mg once-daily
Number of subjects: 20
Study 15329366 — intervention group
Group type: COMPARATOR
Intervention: saquinavir/ritonavir 1600/100 mg once-daily
Number of subjects: 20
Study 10934984 — intervention group
Group type: EXPERIMENTAL
Intervention: β-Blockers
Number of subjects: 0
Study 10934984 — intervention group
Group type: EXPERIMENTAL
Intervention: Various β-Blockers
Number of subjects: 0
Study 9604580 — intervention group
Group type: EXPERIMENTAL
Intervention: Porcelain veneer restorations
Number of subjects: 180
Study 9604580 — intervention group
Group type: COMPARATOR
Intervention: Direct composite veneer restorations
Number of subjects: 180
Study 9604580 — intervention group
Group type: COMPARATOR
Intervention: Indirect composite veneer restorations
Number of subjects: 180
Study 9604580 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall satisfaction
Number of subjects: 180
Study 1286547 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine (20 mg once daily for 4 weeks)
Number of subjects: 29
Study 1286547 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 4036846 — intervention group
Group type: EXPERIMENTAL
Intervention: High P/S ratio diet with high cholesterol (1,000 mg/day)
Number of subjects: 11
Study 4036846 — intervention group
Group type: EXPERIMENTAL
Intervention: High P/S ratio diet with low cholesterol (300 mg/day)
Number of subjects: 11
Study 4036846 — intervention group
Group type: EXPERIMENTAL
Intervention: Low P/S ratio diet with high cholesterol (1,000 mg/day)
Number of subjects: 11
Study 4036846 — intervention group
Group type: EXPERIMENTAL
Intervention: Low P/S ratio diet with low cholesterol (300 mg/day)
Number of subjects: 11
Study 4036846 — intervention group
Group type: EXPERIMENTAL
Intervention: High P/S ratio diet
Number of subjects: 11
Study 31766333 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Organized Games (LOG) approach in PE (n = 282)
Number of subjects: 560
Study 31766333 — intervention group
Group type: COMPARATOR
Intervention: Regular PE (Control group, n = 278)
Number of subjects: 560
Study 30379732 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime-avibactam (CAZ-AVI)
Number of subjects: 0
Study 30379732 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem-vaborbactam
Number of subjects: 0
Study 30379732 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymyxins
Number of subjects: 0
Study 27609406 — intervention group
Group type: EXPERIMENTAL
Intervention: Benralizumab 30 mg every 4 weeks (Q4W)
Number of subjects: 2505
Study 27609406 — intervention group
Group type: EXPERIMENTAL
Intervention: Benralizumab 30 mg every 8 weeks (Q8W)
Number of subjects: 2505
Study 27609406 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2505
Study 27609406 — intervention group
Group type: EXPERIMENTAL
Intervention: Benralizumab (Q4W and Q8W)
Number of subjects: 2505
Study 27609406 — intervention group
Group type: EXPERIMENTAL
Intervention: Benralizumab (Q8W only)
Number of subjects: 2505
Study 25220290 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 ppm F (500 NaF)
Number of subjects: 10
Study 25220290 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 ppm F with 0.25% CaGP (500 NaF CaGP)
Number of subjects: 10
Study 25220290 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 ppm F with 0.25% CaGP (500 MFP CaGP)
Number of subjects: 10
Study 25220290 — intervention group
Group type: COMPARATOR
Intervention: 1100 ppm F (positive control)
Number of subjects: 10
Study 25220290 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 ppm F with 0.25% CaGP (500 NaF CaGP) and 500 ppm F with 0.25% CaGP (500 MFP CaGP)
Number of subjects: 10
Study 22184611 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine (20 mL of different concentrations)
Number of subjects: 39
Study 20705980 — intervention group
Group type: EXPERIMENTAL
Intervention: Tubewells
Number of subjects: 2387
Study 20705980 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid sodium hypochlorite ('Clorin')
Number of subjects: 2387
Study 20705980 — intervention group
Group type: EXPERIMENTAL
Intervention: Hygiene promotion
Number of subjects: 2387
Study 20705980 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of tubewells, Clorin, and hygiene promotion
Number of subjects: 2387
Study 20705980 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2387
Study 17434849 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 21
Study 17434849 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (lopinavir/ritonavir subgroup)
Number of subjects: 21
Study 17434849 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 17434849 — intervention group
Group type: COMPARATOR
Intervention: Placebo (lopinavir/ritonavir subgroup)
Number of subjects: 21
Study 16318697 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibacterial cleaning products
Number of subjects: 224
Study 16318697 — intervention group
Group type: COMPARATOR
Intervention: Nonantibacterial cleaning products
Number of subjects: 224
Study 12064881 — intervention group
Group type: EXPERIMENTAL
Intervention: Intentional ostectomy of the posterior part of the distal segment (test group)
Number of subjects: 61
Study 12064881 — intervention group
Group type: COMPARATOR
Intervention: Traditional sagittal split (control group)
Number of subjects: 61
Study 9524049 — intervention group
Group type: EXPERIMENTAL
Intervention: Talking
Number of subjects: 50
Study 9524049 — intervention group
Group type: EXPERIMENTAL
Intervention: Reading
Number of subjects: 50
Study 9524049 — intervention group
Group type: COMPARATOR
Intervention: Silence
Number of subjects: 50
Study 7822662 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management teaching programs
Number of subjects: 23
Study 2766870 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative antibiotic prophylaxis with 2 x 2 g ceftriaxone (Rocephin)
Number of subjects: 159
Study 2766870 — intervention group
Group type: COMPARATOR
Intervention: No antibiotic prophylaxis
Number of subjects: 159
Study 2766870 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative antibiotic prophylaxis
Number of subjects: 159
Study 338307 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprindine
Number of subjects: 0
Study 338307 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31881040 — intervention group
Group type: EXPERIMENTAL
Intervention: ASPREE framework (type-to-search box with automated coding)
Number of subjects: 19114
Study 31881040 — intervention group
Group type: COMPARATOR
Intervention: Traditional method (free-text only collection and post hoc coding)
Number of subjects: 19114
Study 31881040 — intervention group
Group type: EXPERIMENTAL
Intervention: ASPREE framework
Number of subjects: 19114
Study 31881040 — intervention group
Group type: COMPARATOR
Intervention: Traditional method
Number of subjects: 19114
Study 27669451 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined exercise program (aerobic and resistance) for 12 weeks
Number of subjects: 18
Study 27669451 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 18
Study 26041028 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ferric carboxymaltose (1000 mg)
Number of subjects: 500
Study 26041028 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 500
Study 23853552 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice weekly iron‐folic acid (IFA)
Number of subjects: 1258
Study 23853552 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice weekly multiple micronutrient (MMN)
Number of subjects: 1258
Study 23853552 — intervention group
Group type: COMPARATOR
Intervention: Daily iron‐folic acid (IFA)
Number of subjects: 1258
Study 21160152 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine gel (Instillagel®) during GIS
Number of subjects: 142
Study 21160152 — intervention group
Group type: COMPARATOR
Intervention: Gel without lidocaine (Endosgel®) during GIS
Number of subjects: 142
Study 21160152 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine gel (Instillagel®) during hysteroscopy
Number of subjects: 142
Study 21160152 — intervention group
Group type: COMPARATOR
Intervention: Gel without lidocaine (Endosgel®) during hysteroscopy
Number of subjects: 142
Study 19557003 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased dose of angiotensin‐II receptor blocker (ARB)
Number of subjects: 316
Study 19557003 — intervention group
Group type: COMPARATOR
Intervention: Maintenance dose of ARB plus calcium channel blocker (amlodipine)
Number of subjects: 316
Study 16485881 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% fluorouracil cream (FC) applied once daily for 7 days
Number of subjects: 0
Study 16485881 — intervention group
Group type: COMPARATOR
Intervention: Vehicle cream (VC) applied once daily for 7 days
Number of subjects: 0
Study 15292745 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent exercise (INT‐EX)
Number of subjects: 18
Study 15292745 — intervention group
Group type: COMPARATOR
Intervention: Continuous exercise (CON‐EX)
Number of subjects: 18
Study 15292745 — intervention group
Group type: COMPARATOR
Intervention: No exercise (NOEX)
Number of subjects: 18
Study 11069317 — intervention group
Group type: COMPARATOR
Intervention: Interferon-alpha
Number of subjects: 65
Study 11069317 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha plus colchicine
Number of subjects: 65
Study 9282975 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiplex polymerase chain reaction (MPCR) method
Number of subjects: 37
Study 9282975 — intervention group
Group type: EXPERIMENTAL
Intervention: MPCR method with spiked samples
Number of subjects: 37
Study 9282975 — intervention group
Group type: EXPERIMENTAL
Intervention: MPCR method
Number of subjects: 37
Study 8284632 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate (1 g four times daily for 3 weeks)
Number of subjects: 104
Study 8284632 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study 3126024 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy recruitment
Number of subjects: 316
Study 3126024 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient screening and eligibility
Number of subjects: 316
Study 31174716 — intervention group
Group type: EXPERIMENTAL
Intervention: Advancing Recovery strategies
Number of subjects: 14
Study 31174716 — intervention group
Group type: COMPARATOR
Intervention: Control group (no Advancing Recovery strategies)
Number of subjects: 14
Study 30246694 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (50,000 IU fortnightly)
Number of subjects: 90
Study 30246694 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 27000224 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine (20 mg/day)
Number of subjects: 93
Study 27000224 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study 25212062 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity prevention intervention programme delivered by teachers promoting physical activity and healthy eating; specific dosage and duration not mentioned.
Number of subjects: 0
Study 25212062 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple methods and tools for data collection including observations, logbooks, qualitative evaluation, questionnaires, and research team reflection; specific outcomes not quantified.
Number of subjects: 0
Study 22169080 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid
Number of subjects: 9497
Study 22169080 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9497
Study 22169080 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid with IMPACT model adjustment
Number of subjects: 9497
Study 22169080 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid with CRASH model adjustment
Number of subjects: 9497
Study 21142994 — intervention group
Group type: EXPERIMENTAL
Intervention: In virtuo exposure
Number of subjects: 43
Study 21142994 — intervention group
Group type: EXPERIMENTAL
Intervention: In vivo exposure
Number of subjects: 43
Study 21142994 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list condition
Number of subjects: 43